Abstract Library

#1056 Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases

Introduction: The value of surgical resection in the management of pancreatic neuroendocrine tumor (PNET) with liver metastases (LM) is still debated.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Partelli S

Authors: Partelli S, Inama M, Rinke A, Begum N, Valente R,

Keywords: surgery, metastases, NET, survival,

#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment

Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Falconi M, Spada F,

Keywords: pancreatic neuroendocrine tumor, synchronous liver metastases, debulking, resection, prognostic factors, survival,

#648 Mammalian Target of Rapamycin (mTOR) Expression Analysis and Therapeutic Approach in Primitive (T) and Metastatic (M) Ileal Neuroendocrine Tumors (INT)

Introduction: mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine pancreatic carcinoma therapy. Because of varying behavior, INT are usually excluded from clinical trials employing the mTOR inhibitor, RAD001.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MILIONE M

Authors: Milione M, Pusceddu S, Buzzoni R, Damato A, Coppa J,

Keywords: mTor, midgut, carcinoid,

#645 Loss of Succinate Dehydrogenase (SDHB) in Midgut Carcinoids as Prognostic Factor: A New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?

Introduction: Gene mutations of the succinate dehydrogenase (SDH) complex are involved in the pathogenesis of cancer cells and play a pivotal role in angiogenesis and cell proliferation. The immunoistochemical (IHC) loss of SDHB is a marker of malignancy in pheocromocytomas and paragangliomas.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MILIONE M

Authors: Milione M, Pusceddu S, Buzzoni R, Damato A, Coppa J,

Keywords: midgut, SDHB,

#473 Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?

Introduction: The immunoistochemical (IHC) loss of SDHB expression was reported as a surrogate marker of malignancy in sporadic and familial pheocromocytomas/paragangliomas. SDHB loss is supposed to be tumorigenic (activation hypoxia signals).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Milione M, Pusceddu S, Mazzaferro V, Buzzoni R, De Braud F,

Keywords: SDHB,